Academia

On this page, you will find information on the European Medicines Agency’s (EMA) activities that are most relevant to academia, including news and events. Learn more about the Agency's resources to support medicine development:

Human regulatory: Research and development
Veterinary regulatory: Research and development

Learn more about how EMA interacts with academia.

• List item

  Have your say on EMA's communications - how are we doing?

  Help EMA meet your communication needs by completing EMA's latest communication perception survey. Provide your feedback in 15 minutes by 30 September 2022.

• List item

  Human medicines: highlights of 2021

  In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 54 had a new active substance which had never been authorised in the European Union before. These included four vaccines and five treatments for COVID-19.

• List item

  Medicine repurposing: interactive webinar

  Join our interactive webinar on 17 February 2022 to learn and ask any questions about our joint pilot project with the Heads of Medicines Agencies on repurposing authorised medicines for new indications with important public health benefits. Register by 14 February 2022.

• List item

  Engaging with academia: action plan for 2021 to 2023

  EMA's academia collaboration matrix action plan sets out how EMA intends to create closer ties with academics and researchers in the next two and a half years. It lists actions in five areas: regulatory science and partnerships, innovation and support to academia, communication, events strategy, and training.

• List item

  European medicines agencies network strategy to 2025

  The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.

• List item

  Paediatric medicines: progress on action plan

  A progress update is available on the EMA / European Commission action plan for supporting the development of medicines for children. It specifies the status of each action and outlines concrete achievements to December 2020.

• List item

  Fee waiver for protocol assistance (scientific advice for orphan medicines)

  Applicants from the academic sector can receive free protocol assistance for developing orphan medicines.

• List item

  Coronavirus disease (COVID-19)

  Keep up to date with the latest information on how EMA is handling the COVID-19 pandemic.

• List item

  Supporting medicine developers

  EMA's infosheet highlights the regulatory tools EMA offers to support the development of new and innovative medicines – from the early phases in the laboratory all the way to the patient.

• List item

List item